MITF Modulates Therapeutic Resistance through EGFR Signaling

The Journal of Investigative Dermatology
Zhenyu JiHensin Tsao

Abstract

Response to targeted therapies varies significantly despite shared oncogenic mutations. Nowhere is this more apparent than in BRAF (V600E)-mutated melanomas where initial drug response can be striking and yet relapse is commonplace. Resistance to BRAF inhibitors have been attributed to the activation of various receptor tyrosine kinases (RTKs), although the underlying mechanisms have been largely uncharacterized. Here, we found that EGFR-induced vemurafenib resistance is ligand dependent. We employed whole-genome expression analysis and discovered that vemurafenib resistance correlated with the loss of microphthalmia-associated transcription factor (MITF), along with its melanocyte lineage program, and with the activation of EGFR signaling. An inverse relationship between MITF, vemurafenib resistance, and EGFR was then observed in patient samples of recurrent melanoma and was conserved across melanoma cell lines and patients' tumor specimens. Functional studies revealed that MITF depletion activated EGFR signaling and consequently recapitulated the resistance phenotype. In contrast, forced expression of MITF in melanoma and colon cancer cells inhibited EGFR and conferred sensitivity to BRAF/MEK inhibitors. These findings indica...Continue Reading

References

May 31, 2001·The Journal of Biological Chemistry·M FurumuraV J Hearing
Aug 5, 2006·The Journal of Investigative Dermatology·Guang YangHensin Tsao
Nov 26, 2010·Nature·Cory M JohannessenLevi A Garraway
Oct 14, 2011·The Journal of Investigative Dermatology·Zhenyu JiHensin Tsao
Nov 13, 2012·Molecular Endocrinology·Annavarapu Hari KishoreR Ann Word
Dec 20, 2012·Journal of the National Cancer Institute·Michael P SmithClaudia Wellbrock
Nov 5, 2013·Nature·Cory M JohannessenLevi A Garraway
Apr 29, 2014·Cancer Discovery·David J KonieczkowskiLevi A Garraway

❮ Previous
Next ❯

Citations

Jan 16, 2016·Annual Review of Medicine·Warren Fiskus, Nicholas Mitsiades
Aug 10, 2016·Proceedings of the National Academy of Sciences of the United States of America·Luigi FattoreGennaro Ciliberto
Sep 24, 2015·Cancers·Chandra Prakash PrasadTommy Andersson
Jan 27, 2018·Cell Death & Disease·Gianfranco MattiaPaola Matarrese
Dec 7, 2018·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Kohya KudoKiyoko Fukami
Jun 14, 2017·EMBO Molecular Medicine·Michael P SmithClaudia Wellbrock
Oct 11, 2019·Scientific Reports·Luciana Nogueira de Sousa AndradeRoger Chammas
Feb 6, 2020·International Journal of Molecular Sciences·Francesca Varrone, Emilia Caputo
Dec 20, 2017·Molecular Medicine Reports·Nyoun Soo KwonHye-Young Yun
May 7, 2019·Frontiers in Oncology·Stephen A Luebker, Scott A Koepsell
Aug 17, 2019·Cancers·Azad Saei, Pieter Johan Adam Eichhorn
Dec 9, 2016·Journal of Molecular Cell Biology·Anna de PoloZhi-Min Yuan
May 26, 2017·Cancer·Bobby Y ReddyHensin Tsao
Apr 11, 2019·Nature Reviews. Clinical Oncology·Xue BaiKeith T Flaherty
Nov 19, 2020·Pigment Cell & Melanoma Research·José Pedro Friedmann Angeli, Svenja Meierjohann
Jun 4, 2017·Molecular Cancer Therapeutics·Antonio AhnMichael R Eccles
Nov 30, 2018·Molecular Cancer Therapeutics·David GarandeauNathalie Andrieu-Abadie
Dec 17, 2020·Oncogene·Alexander SwobodaRichard Moriggl
Nov 4, 2020·Neoplasia : an International Journal for Oncology Research·Mai-Huong Thi NguyenNianhan Ma
Nov 8, 2020·The Journal of Investigative Dermatology·Zhenyu JiHensin Tsao
Feb 24, 2021·Nature Biotechnology·Benjamin L EmertArjun Raj
Jul 19, 2018·Cell·Florian RambowJean-Christophe Marine
Apr 6, 2021·Frontiers in Cell and Developmental Biology·Ming Li, Wei Ma
May 1, 2021·International Journal of Molecular Sciences·Julia Katharina Charlotte KreßSvenja Meierjohann
Jun 4, 2021·Molecular Oncology·Barbara MonticoElisabetta Fratta
Aug 8, 2021·International Journal of Molecular Sciences·Yousef SalamaBeate Heissig
Dec 19, 2015·Genes & Development·Roberta FerrettiJacqueline A Lees

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE50509
GSE46517

Methods Mentioned

BETA
exome sequencing
transfection
PCR

Software Mentioned

CompuSyn

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.